BioRev
Book a 30-minute walkthrough

Illustrative only

GeographyUS
Addressable patients1,900,000
Probability of success, base20%
Potential launchQ4 ’32
Peak sales · Base case$520m
Risk-adjusted peak sales$104m
Development spend, next 12 months12%

Market attractiveness

  • Market size5 / 5
  • Unmet need4 / 5
  • Competitive headroom2.5 / 5
  • Pricing potential2 / 5

Why it sits where it does

The biggest peak-sales potential in the set, discounted heavily by a 20% probability of success.

0–5 = attractiveness. A crowded market or a high bar scores low.

Assessment summary

Next decision

Phase II readout 2029 – PoS 20% → 55% if positive.

The nine modules behind this summary are built out on Heart failure (HFrEF) in this preview.

Open the HFrEF workspace